MAZE Maze Therapeutics, Inc.: institutional ownership and insider trading
169 funds reported holding $1.91B of Maze Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $179M, with 36 new positions and 42 funds selling out; over the last 12 months insiders bought $0 and sold $23.7M on the open market.
Famous investors holding MAZE
- Ken Griffin (Citadel Advisors): $26.1M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $5.76M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $359K, 0.0% of the portfolio
Largest institutional holders of MAZE
- Frazier Life Sciences Management, L.P. — $150M
- TRV GP IV, LLC — $134M
- ARCH Venture Management, LLC — $123M
- Deep Track Capital, LP — $111M
- BlackRock, Inc. (BLK) — $105M
- Jupiter Topco LLC — $102M
- JANUS HENDERSON GROUP PLC (JHG) — $85.3M
- T. Rowe Price Investment Management, Inc. — $77.7M
- VANGUARD GROUP INC — $70.3M
- Logos Global Management LP — $57.7M
Recent MAZE insider trades
- Oct 1, 2026: Coloma Jason V sold 34,501 shares ($932K)
- Oct 1, 2026: Bernstein Harold sold 16,141 shares ($435K)
- Sep 29, 2026: Dandekar Atul sold 7,500 shares ($203K)
- Sep 4, 2026: Bernstein Harold sold 9,705 shares ($254K)
5%+ owners
- JANUS HENDERSON GROUP PLC: 5.8% (Schedule 13G/A, filed May 15, 2026)
- BlackRock, Inc.: 5.4% (Schedule 13G, filed Jul 29, 2026)